Professor of Oncology, Professor of Pathology, Johns Hopkins University School of Medicine
Pathology
Dr. Scott E. Kern, MD
|
|
Give Review
Scott Kern works in the field of Pathology. He went to medical school at University of Michigan Medical School. He received awards:"Top Doctors:Baltimore Area", "Top Doctors:Washington-Baltimore" and "Whos Who in Medicine and Healthcare". Scott Kern is also published. He has 100 publications published. The lastest publication: "Genome Annotation by Shotgun Inactivation of a Native Gene in Hemizygous Cells: Application to BRCA2 with Implication of Hypomorphic Variants.'
Publications
- Genome Annotation by Shotgun Inactivation of a Native Gene in Hemizygous Cells: Application to BRCA2 with Implication of Hypomorphic Variants.
- Salivary α-amylase, serum albumin, and myoglobin protect against DNA-damaging activities of ingested dietary agents in vitro.
- Microvascular architecture in a case of gastric antral vascular ectasia (watermelon stomach).
- Hypersensitivities for Acetaldehyde and Other Agents among Cancer Cells Null for Clinically Relevant Fanconi Anemia Genes.
- "Selective cell death mediated by small conditional RNAs" is not selective.
- FAM190A deficiency creates a cell division defect.
- DNA-intercalators causing rapid re-expression of methylated and silenced genes in cancer cells.
- Biological clues to potent DNA-damaging activities in food and flavoring.
- Why Your New Cancer Biomarker May Never Work: Recurrent Patterns and Remarkable Diversity in Biomarker Failures.
- Unbiased discovery of interactions at a control locus driving expression of the cancer-specific therapeutic and diagnostic target, mesothelin.
- Analysis of polymorphisms and haplotype structure of the human thymidylate synthase genetic region: a tool for pharmacogenetic studies.
- Analytic model for academic research productivity having factors, interactions and implications.
- Reexamining a proposal: Thymidylate synthase 5'-untranslated region as a regulator of translation efficiency.
- Structural analysis of the cancer-specific promoter in mesothelin and in other genes overexpressed in cancers.
- FAM190A rearrangements provide a multitude of individualized tumor signatures and neo-antigens in cancer.
- The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting.
- MKK4 as oncogene or tumor suppressor: in cancer and senescence, the story's getting old.
- Where's the passion?
- Improved DNA electrophoresis in conditions favoring polyborates and lewis acid complexation.
- Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene.
- Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influe...
- Hybrids of aneuploid human cancer cells permit complementation of simple and complex cancer defects.
- Ancestral trees for modeling stem cell lineages genetically rather than functionally: understanding mutation accumulation and distinguishing the restrictive cancer ste...
- Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.
- A syngeneic variance library for functional annotation of human variation: application to BRCA2.
- Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward?
- Emerging molecular biology of pancreatic cancer.
- SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients.
- Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer.
- Differential expression of multiple genes in association with MADH4/DPC4/SMAD4 inactivation in pancreatic cancer.
- Precursors to pancreatic cancer.
- High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent MCAT motif.
- The fuzzy math of solid tumor stem cells: a perspective.
- Distinguishing rational from irrational applications of pharmacogenetic synergies from the bench to clinical trials.
- Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer.
- Radiolabeled anti-claudin 4 and anti-prostate stem cell antigen: initial imaging in experimental models of pancreatic cancer.
- High-throughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells.
- Targeting Fanconi anemia/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models.
- MKK4 status predicts survival after resection of gastric adenocarcinoma.
- Copy-number methods dramatically underestimate loss of heterozygosity in cancer.
- Beverage-agarose gel electrophoresis: an inquiry-based laboratory exercise with virtual adaptation.
- Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy.
- Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers.
- Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer.
- Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays.
- A proposed clinical test for monitoring fluoropyrimidine therapy: detection and stability of thymidylate synthase ternary complexes.
- Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options.
- Targeted deletion of MKK4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumo...
- Theoretical proposal: allele dosage of MAP2K4/MKK4 could rationalize frequent 17p loss in diverse human cancers.
- Multiple-criterion evaluation of reported mutations: a proposed scoring system for the intragenic somatic mutation literature.
- Elegance, silence and nonsense in the mutations literature for solid tumors.
- Molecular pathogenesis of pancreatic cancer.
- Does tumorigenesis select for or against mutations of the DNA repair-associated genes BRCA2 and MRE11?: considerations from somatic mutations in microsatellite unstabl...
- In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
- Treatment of familial pancreatic cancer and its precursors.
- Novel genotoxicity assays identify norethindrone to activate p53 and phosphorylate H2AX.
- Pancreaticobiliary cancers with deficient methylenetetrahydrofolate reductase genotypes.
- Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition.
- Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion.
- Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer.
- Stromal responses to carcinomas of the pancreas: juxtatumoral gene expression conforms to the infiltrating pattern and not the biologic subtype.
- Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy.
- MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course.
- Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression.
- Identification of novel highly expressed genes in pancreatic ductal adenocarcinomas through a bioinformatics analysis of expressed sequence tags.
- Ultra-fast high-resolution agarose electrophoresis of DNA and RNA using low-molarity conductive media.
- History and principles of conductive media for standard DNA electrophoresis.
- Stagnation and herd mentality in the biomedical sciences.
- Functional defects in the fanconi anemia pathway in pancreatic cancer cells.
- Nonspecific enhancement of gene expression by compounds identified in high-throughput cell-based screening.
- Functional screen of the fanconi anemia pathway in cancer cells by Fancd2 immunoblot.
- Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds.
- Missense mutations of MADH4: characterization of the mutational hot spot and functional consequences in human tumors.
- Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss.
- The genetics of FANCC and FANCG in familial pancreatic cancer.
- Sodium boric acid: a Tris-free, cooler conductive medium for DNA electrophoresis.
- Polymorphisms of SPINK1 N34S and CFTR in patients with sporadic and familial pancreatic cancer.
- Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major te...
- BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets.
- Analysis of anaphase figures in routine histologic sections distinguishes chromosomally unstable from chromosomally stable malignancies.
- The essential similarity of TGFbeta and activin receptor transcriptional responses in cancer cells.
- Fanconi anemia gene mutations in young-onset pancreatic cancer.
- Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays.
- A double missense variation of the BUB1 gene and a defective mitotic spindle checkpoint in the pancreatic cancer cell line Hs766T.
- Role of the DPC4 tumor suppressor gene in adenocarcinoma of the ampulla of Vater: analysis of 140 cases.
- Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers.
- Whose hypothesis? Ciphering, sectorials, D lesions, freckles and the operation of Stigler's Law.
- Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia.
- An introduction to pancreatic adenocarcinoma genetics, pathology and therapy.
- Pancreatic cancer.
- The desmoplastic response to infiltrating breast carcinoma: gene expression at the site of primary invasion and implications for comparisons between tumor types.
- Quantitative selection constants.
- Fellowship goals for PhDs and MDs: a primer on the molecular biology postdoctoral experience.
- Focus on pancreas cancer.
- Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: sea ur...
- Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.
- Hereditary factors in pancreatic cancer.
- Discovery of novel tumor markers of pancreatic cancer using global gene expression technology.
- Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression.
Schools
University of Mi Med Sch
Doctors Specialties
- Pathology
Accepted Insurances
Awards
- Top Doctors:Baltimore Area
- Top Doctors:Washington-Baltimore
- Whos Who in Medicine and Healthcare
Education
-
Johns Hopkins University -
University of Michigan Hospitals and Health Centers -
University of Michigan Medical School
Helpful Reviews
Similar Doctors
|
|
Dr. Kimberley D. Studeman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas Enelow, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brigitte M. Ronnett, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Toby C. Cornish, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Fanghong Li, MD |
|
|
Dr. Edgar L. Alonsozana, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas A. Heubner, MD
This Doctor is OpenDoctor Recommended.
|